Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Randox Licenses sPLA2 CVD Risk Test from Aterovax

Published: Thursday, May 02, 2013
Last Updated: Wednesday, May 01, 2013
Bookmark and Share
Partnership to develop Aterovax’s patented biomarker sPLA2 for the assessment of cardiovascular risk.

Randox Laboratories Ltd. and Aterovax SA have announced a strategic partnership to commercialize Aterovax’s patented biomarker secreted Phospholipase A2 (sPLA2) for the assessment of cardiovascular risk. Terms of the alliance were not disclosed.

sPLA2 is a novel biomarker that independently and over and above traditional risk factors predicts adverse outcomes in patients with stable coronary artery disease and is useful in the risk stratification of patients with acute coronary syndrome.

Randox have exclusive rights to develop, manufacture and market the new test for use on automated immunoassay analyzers and will develop the sPLA2 test for its own range of analyzers and other diagnostic analyzers.

Dr. Peter FitzGerald CBE FREng, Managing Director at Randox commented “this was an exciting opportunity for Randox to expand its portfolio of CVD biomarkers and demonstrates continued investment in this field. The new SPLA2 test has been shown to add significant clinical value when combined with other biomarkers in the Randox range of tests and offers us the opportunity to provide an effective panel of tests for CVD risk assessment with strong clinical utility. The sPLA2 test will be offered to hospital laboratories through our global distribution network in 145 countries.”

Dr. Gerald Ulrich, CEO of Aterovax believes this strategic partnership will utilize the strengths of Aterovax’s many years research in CVD, especially on the development, role and clinical utility of its patented biomarker (sPLA2) in CVD risk assessment/patient stratification with Randox’s expertise in developing assays for automated immunoassay platforms and “pioneering” novel new assays in CVD biomarkers to establish a sustainable market presence for sPLA2 in the global clinical laboratory market for CVD risk assessment.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!